CFD 属于复杂的高风险金融工具，其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作，以及是否能够接受高额亏损的风险。
US 简体中文
國家 • United States
    實體 • The products and services listed on this website are not available in this location.
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    交易 Aytu BioScience, Inc. - AYTU CFD

    1.736
    5.4%
    • 概括
    • 历史数据
    • 活动
    • 收入报表
    • 资产负债表
    • 现金流
    • 所有权
    交易条件
    价差 0.098
    多头隔夜费

    Long position overnight fee

    Margin. Your investment $1,000.00
    隔夜费用 -0.025457 %
    Charges from borrowed part ($-1.02)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    前往平台
    		-0.025457%
    空头隔夜费

    Short position overnight fee

    Margin. Your investment $1,000.00
    隔夜费用 0.003235 %
    Charges from borrowed part ($0.13)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    前往平台
    		0.003235%
    隔夜费时间 21:00 (UTC)
    最小交易量 0.01
    货币 USD
    保证金 20%
    上市交易所 United States of America
    交易费 0%

    *Information provided by Capital.com

    Aytu Biopharma Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    关键数据
    前收盘价* 1.647
    开仓* 1.597
    1 年变化* 193.03%
    日范围* 1.597 - 1.736
    52 周范围 1.40-16.19
    平均交易量（10 天） 53.76K
    平均交易量（3 个月) 1.67M
    市值 6.88M
    市盈率 -100.00K
    流通股 3.78M
    收入 104.12M
    EPS -206.58
    股息（收益率 %） N/A
    贝塔 -0.37
    下一个财报发布日期 Sep 25, 2023

    所有数据都是由Refinitiv提供的， 除了标有星号的数据， 这是*由 Capital.com 提供的数据

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date 平仓 Change Change (%) 開倉 High Low
    Jun 2, 2023 1.736 0.139 8.70% 1.597 1.736 1.587
    Jun 1, 2023 1.647 0.060 3.78% 1.587 1.667 1.568
    May 31, 2023 1.618 -0.038 -2.29% 1.656 1.657 1.568
    May 30, 2023 1.618 -0.078 -4.60% 1.696 1.697 1.587
    May 26, 2023 1.627 0.000 0.00% 1.627 1.805 1.617
    May 25, 2023 1.618 -0.147 -8.33% 1.765 1.766 1.558
    May 24, 2023 1.746 -0.029 -1.63% 1.775 1.815 1.696
    May 23, 2023 1.765 -0.009 -0.51% 1.774 1.904 1.765
    May 22, 2023 1.874 0.020 1.08% 1.854 1.934 1.824
    May 19, 2023 1.844 0.020 1.10% 1.824 1.934 1.795
    May 18, 2023 1.835 0.020 1.10% 1.815 1.854 1.775
    May 17, 2023 1.736 0.090 5.47% 1.646 1.746 1.607
    May 16, 2023 1.677 0.001 0.06% 1.676 1.795 1.666
    May 15, 2023 1.726 0.011 0.64% 1.715 1.805 1.697
    May 12, 2023 1.776 -0.246 -12.17% 2.022 2.022 1.726
    May 11, 2023 2.022 -0.010 -0.49% 2.032 2.151 1.913
    May 10, 2023 2.002 0.060 3.09% 1.942 2.092 1.804
    May 9, 2023 1.953 0.326 20.04% 1.627 2.052 1.577
    May 8, 2023 1.667 0.208 14.26% 1.459 1.697 1.459
    May 5, 2023 1.480 0.041 2.85% 1.439 1.519 1.341

    Aytu BioScience, Inc. Events

    时间（协调世界时） (UTC) 国家/地区 事件
    Monday, September 25, 2023

    时间（协调世界时） (UTC)

    20:00

    国家/地区

    US

    事件

    Q4 2023 Aytu Biopharma Inc Earnings Release
    Q4 2023 Aytu Biopharma Inc Earnings Release

    Forecast

    -

    Previous

    -
    Monday, November 13, 2023

    时间（协调世界时） (UTC)

    21:00

    国家/地区

    US

    事件

    Q1 2024 Aytu Biopharma Inc Earnings Release
    Q1 2024 Aytu Biopharma Inc Earnings Release

    Forecast

    -

    Previous

    -
    查看所有活動
    • 年度
    • 每季度
    2022 2021 2020 2019 2018
    总收入 96.669 65.632 27.6321 7.32036 3.66012
    收入 96.669 65.632 27.6321 7.32036 3.66012
    收入成本，共计 44.386 36.432 7.55303 2.20204 2.05054
    毛利 52.283 29.2 20.0791 5.11832 1.60958
    总营业费用 208.061 126.071 38.6481 33.9975 17.0825
    销售/一般/行政费用，总计 69.88 55.808 34.8024 19.2396 17.7325
    研究与开发 14.439 5.623 1.72142 0.58907 0.1676
    Depreciation / Amortization 4.067 6.009 4.49047 2.13626 1.55371
    异常费用（收入） 75.289 22.199 -9.91925 9.83055 -4.42185
    营业收入 -111.392 -60.439 -11.016 -26.6772 -13.4224
    利息收入（费用），非经营净值 -0.862 -2.05 -2.60466 -0.45472 3.2345
    税前净收入 -110.283 -58.03 -13.6207 -27.1319 -10.1879
    税后净收入 -110.173 -58.289 -13.6207 -27.1319 -10.1879
    未计算非常项目前的净收益 -110.173 -58.289 -13.6207 -27.1319 -10.1879
    净收入 -110.173 -58.289 -13.6207 -27.1319 -10.1879
    普通股股东可获收益 (不含非经常性项目) -110.173 -58.289 -13.6207 -27.1319 -10.1879
    普通股股东可获收益 (含非經常性項目) -110.173 -58.289 -13.6207 -27.1319 -10.1879
    摊薄净收入 -110.173 -58.289 -13.6207 -27.1319 -10.1879
    摊薄后加权平均股 0.07349 0.83733 0.22596 0.03897 0.00333
    扣除特别项目的每股摊薄盈利 -1499.08 -69.6126 -60.2791 -696.182 -3061.23
    Dividends per Share - Common Stock Primary Issue
    每股正常摊薄盈利 -833.202 -52.3801 -104.177 -443.938 -4389.91
    非常规项目总计 0
    其他，净值 1.971 4.459
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    总收入 22.733 26.279 27.655 27.448 24.199
    收入 22.733 26.279 27.655 27.448 24.199
    收入成本，共计 9.99 8.986 9.623 12.606 11.513
    毛利 12.743 17.293 18.032 14.842 12.686
    总营业费用 31.291 33.072 29.308 45.361 78.685
    销售/一般/行政费用，总计 19.981 18.578 17.424 17.396 17.358
    研究与开发 0.856 1.71 1.064 3.697 3.726
    Depreciation / Amortization 1.198 1.198 1.197 0.853 1.061
    异常费用（收入） 0 2.6 10.809 45.027
    营业收入 -8.558 -6.793 -1.653 -17.913 -54.486
    利息收入（费用），非经营净值 1.358 0.1 1.08 -0.787 -0.055
    其他，净值 -0.128 0.999 1.468
    税前净收入 -7.2 -6.693 -0.701 -17.701 -53.073
    税后净收入 -7.2 -6.693 -0.701 -17.701 -53.073
    未计算非常项目前的净收益 -7.2 -6.693 -0.701 -17.701 -53.073
    净收入 -7.2 -6.693 -0.701 -17.701 -53.073
    普通股股东可获收益 (不含非经常性项目) -7.2 -6.693 -0.701 -17.701 -53.073
    普通股股东可获收益 (含非經常性項目) -7.2 -6.693 -0.701 -17.701 -53.073
    摊薄净收入 -7.2 -6.693 -0.701 -17.701 -53.073
    摊薄后加权平均股 3.72678 3.1103 0.1259 0.08989 1.48449
    扣除特别项目的每股摊薄盈利 -1.93196 -2.15188 -5.56812 -196.925 -35.7516
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    每股正常摊薄盈利 -1.93196 -1.31595 -5.56812 -76.6739 -5.42003
    Other Operating Expenses, Total -0.734
    • 年度
    • 每季度
    2022 2021 2020 2019 2018
    流动资产总额 59.929 105.234 75.4226 15.4329 9.47029
    现金和短期投资 19.36 49.649 48.0817 11.0442 7.01253
    现金等价物 19.36 49.649 48.0817 11.0442 7.01253
    短期投资
    应收账款总额，净额 21.712 28.176 5.63272 1.74079 0.57878
    Accounts Receivable - Trade, Net 21.712 28.176 5.63272 1.74079 0.57878
    Total Inventory 10.849 16.339 9.99944 1.44007 1.33897
    Prepaid Expenses 7.375 9.78 5.71509 0.95778 0.44001
    Total Assets 137.623 265.668 153.293 34.7214 21.0601
    Property/Plant/Equipment, Total - Net 6.296 8.703 0.89261 0.20373 0.21868
    Goodwill, Net 0 65.802 28.0904 0
    Intangibles, Net 70.632 85.464 48.8546 19.0826 11.366
    Other Long Term Assets, Total 0.766 0.465 0.03298 0.0022 0.00509
    Total Current Liabilities 64.442 109.438 28.7634 5.37258 3.39478
    Payable/Accrued 9.468 8.689 0.959
    Accrued Expenses 35.946 49.485 11.1046 1.99724 0.72656
    Notes Payable/Short Term Debt 3.813 7.934 0 0 0
    Other Current Liabilities, Total 4.132 7.407 4.87523 1.07807 0.54855
    Total Liabilities 91.531 128.1 58.2778 27.6336 7.63559
    Total Long Term Debt 14.279 0.18 0 0 0
    Other Liabilities, Total 12.81 18.482 29.5145 22.261 4.24081
    Total Equity 46.092 137.568 95.0153 7.08782 13.4245
    Preferred Stock - Non Redeemable, Net 0 0 0 0.00036 0
    Common Stock 0.004 0.003 0.00126 0.00175 0.00018
    Additional Paid-In Capital 334.56 315.864 215.024 113.475 92.6819
    Retained Earnings (Accumulated Deficit) -288.472 -178.299 -120.01 -106.39 -79.2576
    Total Liabilities & Shareholders’ Equity 137.623 265.668 153.293 34.7214 21.0601
    Total Common Shares Outstanding 1.92894 1.37452 0.62919 0.08769 0.00897
    Other Current Assets, Total 0.633 1.29 5.9936 0.25 0.1
    Accounts Payable 10.987 19.255 11.8246 2.29727 2.11967
    Property/Plant/Equipment, Total - Gross 8.717 9.715 1.37661 0.59973 0.75868
    Accumulated Depreciation, Total -2.421 -1.012 -0.484 -0.396 -0.54
    Total Preferred Shares Outstanding 0 0 3.59498
    Current Port. of LT Debt/Capital Leases 0.096 16.668 0
    Capital Lease Obligations 0.084 0.18 0
    Long Term Debt 14.195
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    流动资产总额 78.465 70.611 74.415 59.929 77.947
    现金和短期投资 19.179 19.501 23.811 19.36 27.613
    现金等价物 19.179 19.501 23.811 19.36 27.613
    应收账款总额，净额 34.043 25.547 27.924 21.712 27.613
    Accounts Receivable - Trade, Net 34.043 25.547 27.924 21.712 27.613
    Total Inventory 13.637 12.95 12.871 10.849 13.891
    Prepaid Expenses 10.429 11.989 9.024 7.375 7.942
    Other Current Assets, Total 1.177 0.624 0.785 0.633 0.888
    Total Assets 147.216 141.436 150 137.623 168.826
    Property/Plant/Equipment, Total - Net 4.395 5.019 5.648 6.296 7.04
    Property/Plant/Equipment, Total - Gross 7.779 8.083 8.384 8.717 8.78
    Accumulated Depreciation, Total -3.384 -3.064 -2.736 -2.421 -1.74
    Goodwill, Net 0 8.637
    Intangibles, Net 63.464 64.985 69.108 70.632 74.428
    Other Long Term Assets, Total 0.892 0.821 0.829 0.766 0.774
    Total Current Liabilities 85.416 67.15 73.204 64.442 80.36
    Accounts Payable 14.673 10.58 14.667 10.987 11.13
    Payable/Accrued 10.287 9.137 8.08 9.468 12.058
    Accrued Expenses 40.55 33.326 34.603 35.946 47.873
    Notes Payable/Short Term Debt 10.403 7.429 8.087 3.813 3.385
    Current Port. of LT Debt/Capital Leases 3.305 0.09 0.925 0.096 0.1
    Other Current Liabilities, Total 6.198 6.588 6.842 4.132 5.814
    Total Liabilities 106.304 95.619 96.094 91.531 107.682
    Total Long Term Debt 11.386 14.533 13.56 14.279 14.167
    Long Term Debt 11.371 14.494 13.498 14.195 14.061
    Capital Lease Obligations 0.015 0.039 0.062 0.084 0.106
    Other Liabilities, Total 9.502 13.936 9.33 12.81 13.155
    Total Equity 40.912 45.817 53.906 46.092 61.144
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.00038 0.00034 0.006 0.004 0.003
    Additional Paid-In Capital 342.584 340.289 345.253 334.56 331.912
    Retained Earnings (Accumulated Deficit) -301.672 -294.472 -291.353 -288.472 -270.771
    Total Liabilities & Shareholders’ Equity 147.216 141.436 150 137.623 168.826
    Total Common Shares Outstanding 3.77951 3.38315 3.12147 1.92894 1.6678
    Total Preferred Shares Outstanding
    Other Equity, Total -0.00038 -0.00034
    • 年度
    • 每季度
    2022 2021 2020 2019 2018
    净收入/起跑线 -110.173 -58.289 -13.6207 -27.1319 -10.1879
    经营活动产生的现金 -28.823 -25.964 -28.3739 -13.8314 -15.9403
    经营活动产生的现金 10.251 9.201 6.24583 2.72707 2.59127
    Deferred Taxes
    非现金物品 81.962 21.443 -8.38913 10.7837 -7.62492
    营运资金的变化 -10.863 1.681 -12.6099 -0.2102 -0.71881
    投资活动产生的现金 -3.248 -2.782 -5.65577 -1.06199 -0.48429
    资本支出 -2.341 0 -0.05985 -0.07471
    其他投资现金流量项目，总计 -3.248 -0.441 -5.65577 -1.00214 -0.40959
    融资活动产生的现金 1.53 30.314 71.0687 19.0751 22.6596
    融资现金流项目 -4.942 -10.996 -5.40415 -1.47996 -2.75752
    股票的发行（报废），净额 11.694 45.051 92.7217 15.555 25.4171
    债务的发行（退还），净额 -5.222 -3.741 -16.2488 5
    现金净变化 -30.541 1.568 37.0391 4.1817 6.23499
    已付现金利息 3.148 1.249 1.04028
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -14.594 -7.394 -2.881 -110.173 -92.472
    Cash From Operating Activities -14.494 -11.588 -9.148 -28.823 -21.728
    Cash From Operating Activities 6.699 4.505 2.328 10.251 8.005
    Non-Cash Items 1.658 3.846 1.488 81.962 67.39
    Cash Interest Paid 2.861 2.021 0.565 3.148 3.08
    Changes in Working Capital -8.257 -12.545 -10.083 -10.863 -4.651
    Cash From Investing Activities 0.038 0.037 0.042 -3.248 -3.207
    Other Investing Cash Flow Items, Total 0.038 0.037 0.042 -3.248 -3.207
    Cash From Financing Activities 14.275 11.692 13.557 1.53 2.647
    Financing Cash Flow Items -5.254 -3.497 -1.107 -4.942 -4.429
    Issuance (Retirement) of Stock, Net 13.012 11.573 10.416 11.694 12.7
    Issuance (Retirement) of Debt, Net 6.517 3.616 4.248 -5.222 -5.624
    Net Change in Cash -0.181 0.141 4.451 -30.541 -22.288
    Capital Expenditures
    投资者名称 投资者类型 流通股百分比 持有股份 股份变动 持有日期 换手率
    Nantahala Capital Management, LLC Hedge Fund 7.1847 271595 0 2023-05-26 LOW
    Alyeska Investment Group, L.P. Hedge Fund 1.984 75000 0 2023-03-31 LOW
    Brooke (Christopher) Individual Investor 1.5438 58357 58357 2022-11-15
    Disbrow (Joshua R.) Individual Investor 1.5235 57591 -3 2023-03-24 LOW
    Renaissance Technologies LLC Hedge Fund 1.3127 49623 -57416 2023-03-31 HIGH
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 1.2503 47263 4379 2023-03-31 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 0.6365 24059 -1 2023-03-31 LOW
    Acadian Asset Management LLC Investment Advisor/Hedge Fund 0.5962 22537 2640 2023-03-31 MED
    Commonwealth Financial Network Investment Advisor 0.4137 15637 159 2023-03-31 LOW
    PGIM Quantitative Solutions LLC Investment Advisor 0.375 14176 5198 2023-03-31 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.3185 12039 -2 2023-03-31 LOW
    Oki (Mark K) Individual Investor 0.2513 9500 0 2023-03-24 LOW
    Pyszczymuka (Greg) Individual Investor 0.2408 9103 5000 2022-12-19
    Cantrell (Gary V.) Individual Investor 0.217 8204 -2000 2022-12-21
    Dockery (Carl C) Individual Investor 0.2157 8152 -2 2023-03-24 LOW
    Liu (Vivian H) Individual Investor 0.1805 6825 0 2023-03-24 HIGH
    Ronald Blue Trust, Inc. Investment Advisor 0.1476 5579 5300 2023-03-31 LOW
    UBS Financial Services, Inc. Investment Advisor 0.1395 5273 5012 2023-03-31 LOW
    Tower Research Capital LLC Hedge Fund 0.0457 1726 113 2023-03-31 HIGH
    Morgan Stanley & Co. LLC Research Firm 0.0228 861 0 2023-03-31 MED

    为什么选择 Capital.com？让我们的数字来说话。

    Capital.com Group

    535K+

    交易者

    87K+

    每月活跃客户

    $113M+

    每月投资额

    $64M+

    每月提取金额

    交易计算器

    如果您在特定日期（选择一个日期）开立差价合约交易并在不同日期（选择一个日期）关闭交易，计算您的假设盈亏。

    交易佣金
    0
    • 1:1
    杠杆
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    投资
    交易规模（杠杆 x 投资）：
    開倉

    平仓

    做空 做多
    過去的表現並不是未來結果的可靠指標
    盈利/盈利/亏损

    Aytu BioScience, Inc. Company profile

    关于 Aytu BioScience Inc.

    Aytu Biopharma, Inc.，前身为Aytu BioScience, Inc.，是一家专业制药公司。 该公司销售的处方产品组合针对初级保健和儿科市场。 公司的主要处方产品用于治疗注意力缺陷多动症（ADHD）和其他常见的儿科疾病。 该公司销售多动症产品Adzenys XR-ODT（安非他命）缓释口服崩解片、Cotempla XR-ODT（哌醋甲酯）缓释口服崩解片和Adzenys-ER（安非他命）缓释口服悬浮液。 公司的其他儿科产品包括Karbinal ER（马来酸卡比诺沙明），一种用于治疗多种过敏性疾病的卡比诺沙明（抗组胺）缓释悬浮液，以及Poly-Vi-Flor和Tri-Vi-Flor，这是两个互补的氟化物处方维生素产品系列，含有氟化物和维生素的组合配方，适用于氟化物缺乏的婴儿和儿童。

    Industry: Pharmaceuticals (NEC)

    373 Inverness Pkwy Ste 206
    80112

    收入报表

    • Annual
    • Quarterly

    人们也观看

    BTC/USD

    27,338.95 Price
    +0.930% 1D Chg, %
    多头隔夜费 -0.0616%
    空头隔夜费 0.0137%
    隔夜费时间 21:00 (UTC)
    价差 60.00

    EUR/USD

    1.07 Price
    -0.020% 1D Chg, %
    多头隔夜费 -0.0096%
    空头隔夜费 0.0014%
    隔夜费时间 21:00 (UTC)
    价差 0.00006

    XRP/USD

    0.55 Price
    +4.180% 1D Chg, %
    多头隔夜费 -0.0753%
    空头隔夜费 0.0069%
    隔夜费时间 21:00 (UTC)
    价差 0.00537

    TSLA

    213.73 Price
    +2.630% 1D Chg, %
    多头隔夜费 -0.0255%
    空头隔夜费 0.0032%
    隔夜费时间 21:00 (UTC)
    价差 0.29

    还在找一位您可以信任的经纪商吗？

    加入成为全球535,000万多名交易者的一份子，选择利用Capital.com进行交易吧。

    1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易